DGIdb - RIBOCICLIB Drug Record

RIBOCICLIB chembl:CHEMBL3545110 ApprovedAntineoplastic

Alternate Names:

LEE011
LEE-011A
NVP-LEE011
RIBOCICLIB
LEE-011
pubchem.compound:44631912
rxcui:1873916
chembl:CHEMBL3545110
drugbank:11730
chemidplus:1211441-98-3

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
FDA Approval	Breast cancer (HR+, HER2-)
Drug Class	Small molecule inhibitor

(8 More Sources)

Publications:

Rader et al., 2013, Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma., Clin. Cancer Res.
Bortolozzi R et al., 2018, Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All)., Biochem Pharmacol
Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
Vu et al., 2016, Targeting mutant NRAS signaling pathways in melanoma., Pharmacol. Res.
Lee HJ et al., 2018, A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer., Cancer Lett
Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
Infante et al., 2016, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas., Clin. Cancer Res.
Dickson, 2014, Molecular pathways: CDK4 inhibitors for cancer therapy., Clin. Cancer Res.
Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
Condorelli R et al., 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer., Ann Oncol
Tripathy et al., 2017, Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors., Clin. Cancer Res.
Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun

RIBOCICLIB CCND2

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
RIBOCICLIB CDK6

Interaction Score: 1.69

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor

Direct Interaction yes

Trial Name LEE011

PMIDs:
24045179 29408328

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD
RIBOCICLIB CCND3

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
RIBOCICLIB CDK4

Interaction Score: 1.2

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name LEE011

Novel drug target Novel Target

Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

PMIDs:
24045179 29408328 25810375

Sources:
ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD
RIBOCICLIB SMARCA4

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30718512

Sources:
CIViC
RIBOCICLIB RB1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27542767 24795392 28151717 29236940

Sources:
JAX-CKB CIViC
RIBOCICLIB CCND1

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29306020

Sources:
ClearityFoundationBiomarkers CIViC
RIBOCICLIB NOTCH1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Everolimus

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB
RIBOCICLIB CDKN2A

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers OncoKB
RIBOCICLIB NRAS

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Binimetinib + Ribociclib

Evidence Type Actionable

Approval Status Phase Ib/II

PMIDs:
26987942

Sources:
JAX-CKB CIViC OncoKB
RIBOCICLIB PGR

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
RIBOCICLIB BRAF

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Encorafenib + Ribociclib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28351928

Sources:
JAX-CKB
RIBOCICLIB ESR2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RIBOCICLIB PIK3CA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25002028

Sources:
CIViC
RIBOCICLIB ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
RIBOCICLIB ESR1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA

MyCancerGenome: RIBOCICLIB
- Version: 20-Jun-2017
Alternate Names:

KISQALI Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Breast cancer (HR+, HER2-)

Publications:
MyCancerGenome: LEE011
- Version: 20-Jun-2017
Alternate Names:

LEE011 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: LEE011
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Ribociclib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Infante et al., 2016, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas., Clin. Cancer Res.

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Dickson, 2014, Molecular pathways: CDK4 inhibitors for cancer therapy., Clin. Cancer Res.

CIViC: RIBOCICLIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Lee HJ et al., 2018, A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer., Cancer Lett

Vu et al., 2016, Targeting mutant NRAS signaling pathways in melanoma., Pharmacol. Res.

Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell

TTD: LEE011
- Version: 2020.06.01
Alternate Names:

D08MXP TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3545110
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: LEE011
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
OncoKB: Ribociclib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
PharmGKB: ribociclib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3545110
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Ribociclib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Cyclin-dependent kinase 6 inhibitor
Direct Interaction	yes
Trial Name	LEE011

Trial Name	LEE011
Novel drug target	Novel Target
Mechanism of Interaction	Cyclin-dependent kinase 4 inhibitor

Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	resistant
Approval Status	Preclinical - Cell culture

combination therapy	Ribociclib + Everolimus
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	sensitive

combination therapy	Binimetinib + Ribociclib
Evidence Type	Actionable
Approval Status	Phase Ib/II

combination therapy	Encorafenib + Ribociclib
Indication/Tumor Type	melanoma
Response Type	sensitive

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

RIBOCICLIB Drug Record

RIBOCICLIB chembl:CHEMBL3545110 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor Direct Interaction yes Trial Name LEE011

PMIDs: 24045179 29408328

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name LEE011 Novel drug target Novel Target Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

PMIDs: 24045179 29408328 25810375

Sources: ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30718512

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type resistant Approval Status Preclinical - Cell culture

PMIDs: 27542767 24795392 28151717 29236940

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29306020

Sources: ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Everolimus Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type sensitive

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers OncoKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Binimetinib + Ribociclib Evidence Type Actionable Approval Status Phase Ib/II

PMIDs: 26987942

Sources: JAX-CKB CIViC OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Encorafenib + Ribociclib Indication/Tumor Type melanoma Response Type sensitive

PMIDs: 28351928

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25002028

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

MyCancerGenome: RIBOCICLIB

Alternate Names: KISQALI Trade Name

Drug Info: Drug Class Small molecule inhibitor FDA Approval Breast cancer (HR+, HER2-)

Publications:

MyCancerGenome: LEE011

Alternate Names: LEE011 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: LEE011

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor

Direct Interaction yes

Trial Name LEE011

PMIDs:
24045179 29408328

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name LEE011

Novel drug target Novel Target

Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

PMIDs:
24045179 29408328 25810375

Sources:
ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

Interaction Types & Directionality:

n/a

PMIDs:
30718512

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27542767 24795392 28151717 29236940

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
29306020

Sources:
ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Everolimus

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Binimetinib + Ribociclib

Evidence Type Actionable

Approval Status Phase Ib/II

PMIDs:
26987942

Sources:
JAX-CKB CIViC OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Encorafenib + Ribociclib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28351928

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25002028

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Alternate Names:

KISQALI Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Breast cancer (HR+, HER2-)

Alternate Names:

LEE011 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Alternate Names:

D08MXP TTD Drug ID